PriceTargets.com logo

WAVE Life Sciences - WVE Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $29.07
  • Forecasted Upside: 75.55%
  • Number of Analysts: 13
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$16.56 As of 12/12/2025 05:00 PM ET
▼ -0.19 (-1.13%)

This chart shows the closing price for WVE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New WAVE Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for WVE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for WVE

Analyst Price Target is $29.07
▲ +75.55% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for WAVE Life Sciences in the last 3 months. The average price target is $29.07, with a high forecast of $40.00 and a low forecast of $21.00. The average price target represents a 75.55% upside from the last price of $16.56.

This chart shows the closing price for WVE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 13 polled investment analysts is to moderate buy stock in WAVE Life Sciences. This rating has held steady since May 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/18/2025
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/16/2025
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/14/2025
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/13/2025
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/13/2025

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/12/2025B. RileyBoost TargetBuy ➝ Buy$19.00 ➝ $37.00
12/12/2025WedbushBoost TargetOutperform ➝ Outperform$20.00 ➝ $33.00
12/9/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$16.00 ➝ $29.00
12/9/2025UBS GroupSet Target$30.00
12/9/2025CitigroupBoost TargetBuy ➝ Buy$16.00 ➝ $30.00
12/9/2025Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$12.00 ➝ $34.00
12/8/2025Royal Bank Of CanadaUpgradeSector Perform ➝ Outperform$9.00 ➝ $27.00
12/8/2025Raymond James FinancialReiterated RatingOutperform ➝ Outperform$21.00
12/8/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$19.00 ➝ $40.00
12/8/2025Morgan StanleySet Target$28.00
12/8/2025Leerink PartnersReiterated RatingOutperform ➝ Outperform
11/11/2025WedbushBoost TargetOutperform ➝ Outperform$18.00 ➝ $20.00
11/11/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$18.00 ➝ $16.00
10/27/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$12.00
10/20/2025Wells Fargo & CompanyInitiated CoverageOverweight$18.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/4/2025B. RileyReiterated RatingBuy ➝ Buy
9/4/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$21.00 ➝ $18.00
9/3/2025Leerink PartnersSet Target$26.00
9/3/2025HC WainwrightReiterated RatingBuy ➝ Buy$22.00
8/4/2025Canaccord Genuity GroupInitiated CoverageBuy$19.00
7/31/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$24.00 ➝ $21.00
7/28/2025OppenheimerInitiated CoverageOutperform$24.00
7/16/2025CitigroupInitiated CoverageBuy$16.00
6/23/2025WedbushReiterated RatingOutperform ➝ Outperform$18.00
6/11/2025Raymond James FinancialInitiated CoverageOutperform$14.00
4/29/2025Cantor FitzgeraldInitiated CoverageOverweight$10.00
4/8/2025WedbushInitiated CoverageOutperform$18.00
3/26/2025HC WainwrightReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
3/5/2025HC WainwrightReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
2/25/2025Jefferies Financial GroupInitiated CoverageBuy$26.00
11/21/2024MizuhoBoost TargetOutperform ➝ Outperform$19.00 ➝ $22.00
11/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
11/12/2024Truist FinancialBoost TargetBuy ➝ Buy$17.00 ➝ $36.00
11/4/2024B. RileyBoost TargetBuy ➝ Buy$19.00 ➝ $22.00
10/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
10/21/2024Royal Bank Of CanadaBoost TargetSector Perform ➝ Sector Perform$7.00 ➝ $15.00
10/17/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$13.00 ➝ $17.00
10/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
10/16/2024Leerink PartnersBoost TargetOutperform ➝ Outperform$20.00 ➝ $22.00
10/16/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$11.00 ➝ $22.00
10/16/2024Raymond James FinancialUpgradeOutperform ➝ Strong-Buy$13.00 ➝ $22.00
10/4/2024Royal Bank Of CanadaBoost TargetSector Perform ➝ Sector Perform$5.00 ➝ $7.00
10/3/2024B. RileyBoost TargetBuy ➝ Buy$11.00 ➝ $19.00
9/27/2024JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$10.00 ➝ $13.00
9/25/2024HC WainwrightBoost TargetBuy ➝ Buy$15.00 ➝ $22.00
9/19/2024B. RileyInitiated CoverageBuy$11.00
9/9/2024JPMorgan Chase & Co.Initiated CoverageOverweight$10.00
6/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
6/25/2024MizuhoReiterated RatingOutperform ➝ Outperform$19.00 ➝ $19.00
5/15/2024Wells Fargo & CompanyInitiated CoverageOverweight$11.00
4/1/2024Truist FinancialReiterated RatingBuy ➝ Buy$17.00
3/7/2024Royal Bank Of CanadaReiterated RatingSector Perform ➝ Sector Perform$5.00
3/7/2024HC WainwrightBoost TargetBuy ➝ Buy$8.00 ➝ $15.00
12/19/2023Leerink PartnrsUpgradeMarket Perform ➝ Outperform
12/19/2023Leerink PartnersUpgradeMarket Perform ➝ Outperform$5.00 ➝ $12.00
8/4/2023Leerink PartnrsReiterated RatingMarket Perform
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$8.00
7/5/2023Raymond James FinancialInitiated CoverageOutperform$7.00
5/24/2023MizuhoLower Target$13.00 ➝ $10.00
5/23/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$7.00 ➝ $5.00
4/14/2023MizuhoReiterated RatingBuy$13.00
3/23/2023HC WainwrightReiterated RatingBuy$8.00
12/14/2022Leerink PartnersBoost TargetMarket Perform$2.00 ➝ $7.00
11/11/2022Royal Bank Of CanadaLower TargetSector Perform$8.00 ➝ $5.00
10/24/2022Leerink PartnersReiterated RatingMarket Perform
5/13/2022HC WainwrightLower Target$10.00 ➝ $8.00
3/4/2022HC WainwrightReiterated RatingBuy$10.00
9/29/2021HC WainwrightReiterated RatingBuy$10.00
5/19/2021MizuhoBoost TargetBuy$7.00 ➝ $8.00
3/30/2021Truist FinancialLower Target$27.00 ➝ $17.00
3/30/2021Leerink PartnersLower TargetMarket Perform$10.00 ➝ $7.00
3/30/2021MizuhoLower TargetBuy$21.00 ➝ $7.00
3/30/2021Royal Bank Of CanadaLower TargetSector Perform$13.00 ➝ $8.00
3/11/2021MizuhoBoost TargetBuy$19.00 ➝ $21.00
3/7/2021Royal Bank Of CanadaReiterated RatingHold
3/7/2021Leerink PartnersReiterated RatingHold$10.00
12/15/2020HC WainwrightReiterated RatingBuy$20.00
(Data available from 12/13/2020 forward)

News Sentiment Rating

1.05 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 32 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/17/2025
  • 17 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/16/2025
  • 6 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/16/2025
  • 14 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/15/2025
  • 19 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/14/2025
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/14/2025
  • 7 very positive mentions
  • 33 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/13/2025
  • 45 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/13/2025

Current Sentiment

  • 45 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

WAVE Life Sciences logo
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Read More

Today's Range

Now: $16.56
Low: $15.86
High: $17.77

50 Day Range

MA: $8.66
Low: $6.67
High: $21.31

52 Week Range

Now: $16.56
Low: $5.28
High: $21.73

Volume

8,093,027 shs

Average Volume

12,570,605 shs

Market Capitalization

$2.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of WAVE Life Sciences?

The following equities research analysts have issued stock ratings on WAVE Life Sciences in the last twelve months: B. Riley, Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., HC Wainwright, Jefferies Financial Group Inc., Leerink Partners, Morgan Stanley, Oppenheimer Holdings, Inc., Raymond James Financial, Inc., Royal Bank Of Canada, UBS Group AG, Wall Street Zen, Wedbush, Weiss Ratings, and Wells Fargo & Company.
View the latest analyst ratings for WVE.

What is the current price target for WAVE Life Sciences?

0 Wall Street analysts have set twelve-month price targets for WAVE Life Sciences in the last year. Their average twelve-month price target is $29.07, suggesting a possible upside of 75.6%. Canaccord Genuity Group Inc. has the highest price target set, predicting WVE will reach $40.00 in the next twelve months. Raymond James Financial, Inc. has the lowest price target set, forecasting a price of $21.00 for WAVE Life Sciences in the next year.
View the latest price targets for WVE.

What is the current consensus analyst rating for WAVE Life Sciences?

WAVE Life Sciences currently has 1 sell rating and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for WVE.

What other companies compete with WAVE Life Sciences?

Other companies that are similar to WAVE Life Sciences include Avidity Biosciences, Elanco Animal Health, Qiagen, Abivax and Arrowhead Pharmaceuticals. Learn More about companies similar to WAVE Life Sciences.

How do I contact WAVE Life Sciences' investor relations team?

WAVE Life Sciences' physical mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company's listed phone number is (656) 236-3388 and its investor relations email address is [email protected]. The official website for WAVE Life Sciences is www.wavelifesciences.com. Learn More about contacing WAVE Life Sciences investor relations.